JP2003038158A - Purified concentrate having inhibitory action on crisis of hepatopathy collected from distillation residual liquid of barley shochu (japanese distilled spirit) and method for producing the same - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a purified concentrate which is collected from distillation residual liquid of barley Shochu (Japanese distilled spirit) and has a strongly inhibitory action on crisis of hepatopathy (orotic acid-induced hepar adiposum and D-galactosamine-induced hepatitis) and to provide method for producing the same. SOLUTION: This purified concentrate is collected by subjecting a distillation residual liquid of barley Shochu prepared as a by-product in production of Shochu using barley as a raw material to solid-liquid separation to give a liquid component, subjecting the liquid component to adsorption treatment using a synthetic adsorbent to give an adsorbed fraction and extracting the adsorbed fraction with an alkali or ethanol and has an inhibitory action on crisis of orotic acid-induced hepar adiposum and/or D-galactosamine-induced hepatitis. This method for producing the purified concentrate is provided.

Description

【発明の詳細な説明】Detailed Description of the Invention

【０００１】[0001]

【発明が属する技術分野】本発明は大麦を原料とする焼
酎製造において副成する大麦焼酎蒸留残液を固液分離し
て液体分を得、該液体分を合成吸着剤を用いる吸着処理
に付して吸着画分を得、該吸着画分をアルカリ又はエタ
ノールを用いて溶出することにより得られる脱着画分か
らなる肝障害（オロチン酸誘発性脂肪肝及び/又はD-ガ
ラクトサミン誘発性肝炎）の発症を抑制する作用を有す
る精製濃縮物及びその製造方法に関する。以下の本発明
に係わる記載において肝障害と云う場合、該肝障害は、
オロチン酸誘発性脂肪肝及び/又はD-ガラクトサミン誘
発性肝炎を意味する。TECHNICAL FIELD The present invention relates to a liquid fraction obtained by solid-liquid separation of a barley shochu distillation residual liquid by-produced in the production of shochu using barley as a raw material, and the liquid fraction is subjected to an adsorption treatment using a synthetic adsorbent. To obtain an adsorption fraction, and the onset of liver injury (orotic acid-induced fatty liver and / or D-galactosamine-induced hepatitis) consisting of a desorption fraction obtained by eluting the adsorption fraction with alkali or ethanol. The present invention relates to a purified concentrate having an action of suppressing the above and a method for producing the same. In the following description relating to the present invention, when referred to as liver disorder, the liver disorder is
It means orotic acid-induced fatty liver and / or D-galactosamine-induced hepatitis.

【０００２】[0002]

【従来の技術】肝障害の一つとして知られる肝炎の中で
は、ウイルスを原因とするウイルス性肝炎が最も多く、
該ウイルス性肝炎は肝臓に肝炎ウイルスが住み着くこと
によって引き起こされる。特にB型肝炎とC型肝炎は、肝
硬変や肝臓がんへの移行率が極めて高いことが知られて
いる。これとは別に、脂肪肝と称される疾患も肝障害の
一つであり、該脂肪肝は、エネルギーの過剰摂取や運動
不足等によって、肝臓の肝細胞中に過剰の中性脂肪が蓄
積した状態をいい、心筋梗塞や動脈硬化などの生活習慣
病を引き起こす原因となることが知られている。Background Art Among hepatitis known as one of liver disorders, viral hepatitis caused by a virus is the most common,
The viral hepatitis is caused by the hepatitis virus colonizing the liver. In particular, hepatitis B and hepatitis C are known to have extremely high rates of transition to liver cirrhosis and liver cancer. Aside from this, a disease called fatty liver is also one of liver disorders, and excessive fatty acid accumulated in the liver hepatocytes due to excessive intake of energy or lack of exercise. It refers to the condition and is known to cause lifestyle-related diseases such as myocardial infarction and arteriosclerosis.

【０００３】ところで、日本栄養・食糧学会総会講演要
旨集、Vol.53, 53(1999)には、大麦焼酎を製造する際に
副成される大麦焼酎蒸留残液がオロチン酸投与によるラ
ットの肝臓への脂質の蓄積、即ち、脂肪肝の発症を抑制
する作用を有することが報告されている。また日本醸造
協会誌、Vol.94, No.9, 768(1999)には、大麦焼酎蒸留
残液が有するこうしたオロチン酸誘発性脂肪肝の発症抑
制作用は、ワイン粕やビール粕に比べて強く、該作用は
いも焼酎蒸留残液には全く認められず、米焼酎蒸留残液
では極めて小さいことから、大麦焼酎蒸留残液のみに特
有のものであることが報告されている。更に、日本醸造
協会誌、Vol.95, No.9, 706(2000)には、該大麦焼酎蒸
留残液が、ウイルス性肝障害と同様の症状を呈すること
が知られているD-ガラクトサミン誘発性肝炎に対する発
症抑制効作用があり、該作用は大麦焼酎蒸留残液を遠心
分離に付すことにより得られる液体分に認められること
が報告されている。By the way, in the Proceedings of the Annual Meeting of the Japan Society of Nutrition and Food Science, Vol. 53, 53 (1999), the barley shochu distillation residual liquid by-produced during the production of barley shochu is the liver of rats treated with orotic acid. It has been reported that it has an action of suppressing lipid accumulation in the liver, that is, the development of fatty liver. In addition, the Journal of the Brewing Society of Japan, Vol.94, No.9, 768 (1999), barley shochu distillation residual liquid has such an orotate-induced fatty liver suppressive effect is stronger than wine lees and beer lees. However, this effect was not observed at all in the potato liquor distillation bottom liquor and was extremely small in the rice liquor distillation bottom liquor, so it was reported that it was unique only to the barley liquor distillation bottom liquor. Furthermore, in the Journal of the Brewing Society of Japan, Vol.95, No.9, 706 (2000), the barley shochu distillation residual liquid is known to exhibit the same symptoms as viral liver injury, D-galactosamine induction. It has been reported that it has an onset-suppressing effect on sexual hepatitis, and that this effect is observed in the liquid component obtained by subjecting the barley shochu distillation residual liquid to centrifugation.

【０００４】[0004]

【発明が解決しようとする課題】しかしながら、該大麦
焼酎蒸留残液に含まれる上述した肝障害の発症抑制作用
に寄与する成分は見極められてはいない。またそうした
成分を分取して精製濃縮した精製濃縮物は全く知られて
いない。こうしたことから、該大麦焼酎蒸留残液を前記
肝障害の発症抑制に使用する場合には、該大麦焼酎蒸留
残液をそのまま摂取する以外他に方法は無い。その場
合、該大麦焼酎蒸留残液による所望の肝障害発症抑制作
用を得るためには、該大麦焼酎蒸留残液を凍結乾燥して
凍結乾燥物にしたところで、該凍結乾燥物を多量に摂取
する必要がある。However, the components contained in the barley shochu distillation residual liquid that contribute to the above-mentioned inhibitory action on liver injury have not been identified. Further, there is no known purified concentrate obtained by separating and purifying such components. For this reason, when the barley shochu distillation residual liquid is used for suppressing the onset of the liver damage, there is no other method than ingesting the barley shochu distillation residual liquid as it is. In that case, in order to obtain the desired liver injury suppressive action by the barley shochu distillation residual liquid, the barley shochu distillation residual liquid is freeze-dried into a freeze-dried product, and the freeze-dried product is ingested in a large amount. There is a need.

【０００５】[0005]

【課題を解決するための手段】上記問題を解決すべく本
発明者らが、実験を介して鋭意検討を行ったところ、驚
くべきことに、大麦焼酎蒸留残液を固液分離して液体分
を得、該液体分を合成吸着剤を用いる吸着処理に付して
吸着画分を得、該吸着画分をアルカリ又はエタノールを
用いて溶出することにより得られる脱着画分が肝障害
（オロチン酸誘発性脂肪肝及びD-ガラクトサミン誘発性
肝炎）の発症を極めて強力に抑制する作用を有すること
を見出した。本発明は、この発見に基づいて完成に至っ
たものである。即ち本発明は、従来、肝障害の発症を抑
制する作用を有する食品或いは医薬品を得る目的で積極
的に使用されることのなかった発酵残渣の一種である大
麦焼酎蒸留残液から肝障害（オロチン酸誘発性脂肪肝及
びD-ガラクトサミン誘発性肝炎）の発症を極めて強力に
抑制する作用を有する精製濃縮物及びその製造方法を提
供するものである。Means for Solving the Problems The inventors of the present invention have conducted extensive studies through experiments to solve the above problems. Surprisingly, barley shochu distillation residual liquid is solid-liquid separated to obtain liquid components. And the liquid fraction is subjected to adsorption treatment using a synthetic adsorbent to obtain an adsorption fraction, and the desorption fraction obtained by eluting the adsorption fraction with alkali or ethanol is a liver disorder (orotic acid It has been found that it has an extremely strong inhibitory effect on the onset of induced fatty liver and D-galactosamine-induced hepatitis. The present invention has been completed based on this discovery. That is, the present invention, from the barley shochu distillation residual liquid, which is a kind of fermentation residue that has not been positively used for the purpose of obtaining a food or a drug having an action of suppressing the onset of liver damage, has a liver damage (orotene). The present invention provides a purified concentrate having an action of extremely strongly suppressing the onset of acid-induced fatty liver and D-galactosamine-induced hepatitis), and a method for producing the same.

【０００６】本発明者らは、上述した従来技術に鑑みて
実験を介して鋭意検討を行った。即ち、本発明者らは、
後に述べる実験（実験1-A）を介して、大麦焼酎蒸留残
液を遠心分離に付して液体分（a）と固体分（b）とを分
取し、該液体分と該個体分をそれぞれ別々に凍結乾燥に
付して該液体分の凍結乾燥粉末（a-i）及び該固体分の
凍結乾燥粉末（b-i）を得、該凍結乾燥粉末（a-i）及び
該凍結乾燥粉末（b-i）のそれぞれに、オロチン酸を混
和させてラットに投与して実験を行った。その結果、肝
臓重量、肝臓総脂質濃度、肝臓コレステロール濃度、及
び肝臓トリグリセリド濃度は、前記固体分の凍結乾燥粉
末（b-i）にオロチン酸を混和させたもので顕著に増加
したが、前記液体分の凍結乾燥粉末（a-i）にオロチン
酸を混和させたものでは基本食の正常値に近似した値を
示した。一方、血清総コレステロール濃度、血清HDL-コ
レステロール濃度、血清トリグリセリド濃度、及び血清
リン脂質濃度は、前記固体分の凍結乾燥粉末（b-i）に
オロチン酸を混和させたものでは明らかに低下したが、
前記液体分の凍結乾燥粉末（a-i）にオロチン酸を混和
させたものでは基本食の正常値に近似した値を示した。
すなわち、前記固体分の凍結乾燥粉末（b-i）は肝障害
の抑制に全く寄与しないが、前記液体分の凍結乾燥粉末
（a-i）は肝障害の発生を抑制することが判った。The present inventors have conducted extensive studies through experiments in view of the above-mentioned conventional technique. That is, the present inventors
Through an experiment described later (Experiment 1-A), the barley shochu distillation residual liquid was subjected to centrifugation to separate a liquid content (a) and a solid content (b), and the liquid content and the solid content were separated. Lyophilized separately to obtain the freeze-dried powder (ai) for the liquid and the freeze-dried powder (bi) for the solid, and the freeze-dried powder (ai) and the freeze-dried powder (bi) respectively. The experiment was performed by mixing orotate and administering it to rats. As a result, the liver weight, total liver lipid concentration, liver cholesterol concentration, and liver triglyceride concentration increased remarkably when the lyophilized powder (bi) of the solid component was mixed with orotic acid, but The lyophilized powder (ai) mixed with orotic acid showed a value close to the normal value of the basic diet. On the other hand, the serum total cholesterol concentration, the serum HDL-cholesterol concentration, the serum triglyceride concentration, and the serum phospholipid concentration were clearly reduced in the lyophilized powder of the solid (bi) mixed with orotic acid,
The lyophilized powder (ai) of the liquid component mixed with orotic acid showed a value close to the normal value of the basic diet.
That is, it was found that the freeze-dried powder (bi) for the solid content does not contribute to the suppression of liver damage at all, but the freeze-dried powder (ai) for the liquid content suppresses the occurrence of liver damage.

【０００７】そこで、本発明者らは、後に述べる実験
（実験2-A）を介して、大麦焼酎蒸留残液から得られた
上述の液体分に含まれるどのような成分がオロチン酸誘
発性脂肪肝に対する発症抑制作用を示すかを明らかにす
るために以下の実験を行った。即ち、上記大麦焼酎蒸留
残液の液体分(a) を合成吸着剤を用いる吸着処理に付し
て吸着画分を得、該吸着画分をアルカリを用いて溶出す
ることにより得られる脱着画分を凍結乾燥して得られた
粉末にオロチン酸を混和させてラットに投与して実験を
行った。その結果、該ラットの肝臓重量、肝臓総脂質濃
度、肝臓コレステロール濃度、及び肝臓トリグリセリド
濃度は基本食の正常値と実質的に同等の値を示し、血清
総コレステロール濃度、血清HDL-コレステロール濃度、
血清トリグリセリド濃度、及び血清リン脂質濃度も基本
食の正常値と実質的に同等の値を示し、脂肪肝の発症が
ほとんど完全に抑制されることが判明した。すなわち、
上記大麦焼酎蒸留残液の液体分(a) を合成吸着剤を用い
る吸着処理に付して吸着画分を得、該吸着画分をアルカ
リを用いて溶出することにより得られる脱着画分の凍結
乾燥粉末はオロチン酸誘発性脂肪肝の発症をほとんど完
全に抑制することが判った。一方、上記大麦焼酎蒸留残
液の液体分(a) を合成吸着剤を用いる吸着処理に付した
際の非吸着画分を分画し、該非吸着画分を凍結乾燥して
得られた粉末にオロチン酸を混和させてラットに投与し
て実験を行った。その結果、該ラットの肝臓重量、肝臓
総脂質濃度、肝臓コレステロール濃度、及び肝臓トリグ
リセリド濃度は基本食の正常値とは実質的に異なる値を
示し、血清総コレステロール濃度、血清HDL-コレステロ
ール濃度、血清トリグリセリド濃度、及び血清リン脂質
濃度も基本食の正常値とは実質的に異なる値を示し、オ
ロチン酸誘発性脂肪肝の発症を全く抑制しないことが判
明した。以上の実験結果から、大麦焼酎蒸留残液が有す
るオロチン酸誘発性脂肪肝の発症抑制に寄与する成分
は、前記大麦焼酎蒸留残液を固液分離して得られた液体
分を合成吸着剤を用いる吸着処理に付すことにより得ら
れる吸着画分をアルカリ又はエタノールを用いて溶出す
ることにより得られる脱着画分に存在することが判明し
た。[0007] Therefore, the present inventors have conducted an experiment (Experiment 2-A) described later to find out what component contained in the above-mentioned liquid obtained from the barley shochu distillation residual liquid is an orotic acid-induced fat. The following experiment was conducted in order to clarify whether or not it has an onset suppressing effect on the liver. That is, the liquid fraction (a) of the barley shochu distillation residue is subjected to an adsorption treatment using a synthetic adsorbent to obtain an adsorption fraction, and the desorption fraction obtained by eluting the adsorption fraction with an alkali. The experiment was carried out by mixing orotate with the powder obtained by freeze-drying and administering the mixture to rats. As a result, the liver weight of the rat, the liver total lipid concentration, the liver cholesterol concentration, and the liver triglyceride concentration show a value substantially equivalent to the normal value of the basic diet, serum total cholesterol concentration, serum HDL-cholesterol concentration,
The serum triglyceride concentration and serum phospholipid concentration also showed values substantially equivalent to the normal values of the basic diet, and it was revealed that the development of fatty liver was almost completely suppressed. That is,
Liquid fraction of the barley shochu distillation residual liquid (a) is subjected to an adsorption treatment using a synthetic adsorbent to obtain an adsorption fraction, and the desorption fraction obtained by elution of the adsorption fraction with an alkali is frozen. It was found that dry powder almost completely suppressed the development of orotic acid-induced fatty liver. On the other hand, the liquid fraction of the barley shochu distillation residual liquid (a) was subjected to adsorption treatment using a synthetic adsorbent to fractionate the non-adsorption fraction, and the non-adsorption fraction was freeze-dried to obtain a powder. The experiment was conducted by mixing orotate and administering it to rats. As a result, the liver weight, liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration of the rat showed a value substantially different from the normal value of the basic diet, and serum total cholesterol concentration, serum HDL-cholesterol concentration, serum The triglyceride concentration and the serum phospholipid concentration also showed values substantially different from the normal values of the basic diet, and it was found that the development of orotate-induced fatty liver was not suppressed at all. From the above experimental results, the component that contributes to the suppression of the development of orotate-induced fatty liver in the barley shochu distillation residual liquid is a synthetic adsorbent obtained by solid-liquid separation of the barley shochu distillation residual liquid. It was found that the adsorption fraction obtained by subjecting to the adsorption treatment used was present in the desorption fraction obtained by eluting with an alkali or ethanol.

【０００８】更に、本発明者らは、後に述べる実験（実
験2-B）を介して、大麦焼酎蒸留残液を固液分離して得
られた液体分に含まれるどのような成分がD-ガラクトサ
ミン誘発性肝炎の発症抑制作用を示すかを明らかにする
ために以下の実験を行った。即ち、大麦焼酎蒸留残液を
固液分離して得られた液体分（a）を合成吸着剤を用い
る吸着処理に付して吸着画分を得、該吸着画分をアルカ
リを用いて溶出することにより得られる脱着画分を凍結
乾燥することにより得られた粉末を飼料に2重量%混和さ
せて一定期間ラットに自由摂取させた後、該ラットの腹
腔内にD-ガラクトサミンを投与し、所定時間経過後に、
血清中のGOT及びGPTを測定した。その結果、該脱着画分
を2重量%含む飼料を摂取したラットは、該脱着画分を含
まない対照食からなる飼料を摂取したラットに比べて有
意に低いGOT及びGPTの値を示した。このことから該脱着
画分はD-ガラクトサミン誘発性肝炎に対する顕著な発症
抑制作用を有することが判明した。一方、上記合成吸着
剤による吸着処理の際に得られた非吸着画分を凍結乾燥
して得られた粉末を飼料に2重量%混和させて一定期間ラ
ットに自由摂取させた後、該ラットの腹腔内にD-ガラク
トサミンを投与し、所定時間経過後に、血清中のGOT及
びGPTを測定した。その結果、該非吸着画分を2重量%含
む飼料を摂取したラットは、該非吸着画分を含まない対
照食からなる飼料を摂取したラットと比べてわずかに低
いGOT及びGPTの値を示した。このことから該非吸着画分
はD-ガラクトサミン誘発性肝炎に対する発症抑制作用が
極めて小さいことが判明した。以上の実験結果から、大
麦焼酎蒸留残液が有するD-ガラクトサミン誘発性肝炎の
発症抑制に寄与する成分は、該大麦焼酎蒸留残液固液分
離して得られた液体分を合成吸着剤を用いる吸着処理に
付すことにより得られる吸着画分をアルカリ又はエタノ
ールを用いて溶出することにより得られる脱着画分に極
めて濃縮された状態で存在することが判明した。Further, the inventors of the present invention conducted, through an experiment (Experiment 2-B) described later, what component D- contained in the liquid component obtained by solid-liquid separation of the barley shochu distillation residual liquid. The following experiment was conducted in order to clarify whether it has a suppressive effect on the onset of galactosamine-induced hepatitis. That is, the liquid component (a) obtained by solid-liquid separation of the barley shochu distillation residual liquid is subjected to an adsorption treatment using a synthetic adsorbent to obtain an adsorption fraction, and the adsorption fraction is eluted with an alkali. The powder obtained by freeze-drying the desorption fraction obtained by mixing 2% by weight in the feed and allowed to freely ingest the rat for a certain period, D-galactosamine was administered intraperitoneally to the rat, predetermined After the passage of time,
GOT and GPT in serum were measured. As a result, the rats that received the diet containing 2% by weight of the desorption fraction showed significantly lower GOT and GPT values than the rats that consumed the control diet that did not contain the desorption fraction. From this, it was revealed that the desorbed fraction had a remarkable onset suppressing action on D-galactosamine-induced hepatitis. On the other hand, the powder obtained by freeze-drying the non-adsorbed fraction obtained during the adsorption treatment with the synthetic adsorbent was admixed with 2% by weight of the feed and allowed to be freely ingested by the rat for a certain period of time, D-galactosamine was intraperitoneally administered, and after a lapse of a predetermined time, serum GOT and GPT were measured. As a result, the rats that received the feed containing the non-adsorbed fraction at 2% by weight showed slightly lower GOT and GPT values than the rats that received the control diet that did not contain the non-adsorbed fraction. From this, it was revealed that the non-adsorbed fraction had a very small effect of suppressing the onset of D-galactosamine-induced hepatitis. From the above experimental results, the component that contributes to the suppression of the onset of D-galactosamine-induced hepatitis in the barley shochu distillation residual liquid is a synthetic adsorbent using the liquid component obtained by solid-liquid separation of the barley shochu distillation residual liquid. It was found that the adsorption fraction obtained by subjecting to the adsorption treatment was present in a very concentrated state in the desorption fraction obtained by eluting with an alkali or ethanol.

【０００９】上述したように本発明者らは、大麦を原料
とする焼酎製造において副成する大麦焼酎蒸留残液を固
液分離して液体分を得、該液体分を合成吸着剤を用いる
吸着処理に付して吸着画分を得、該吸着画分をアルカリ
又はエタノールを用いて溶出することにより得られる精
製濃縮物が、未処理の大麦焼酎蒸留残液よりも極めて強
力な肝障害発症抑制作用、即ち、オロチン酸誘発性脂肪
肝の発症を強力に抑制する作用及びD-ガラクトサミン誘
発性肝炎の発症を強力に抑制する作用を有することを見
出した。大麦焼酎蒸留残液についてのこの発見は、今ま
でに全く例のない新事実であり、大麦焼酎蒸留残液を肝
障害の罹患予防目的で食品或いは医薬として使用できる
という大麦焼酎蒸留残液の新規な用途を創出するもので
ある。本発明は、食品或いは医薬として有効に使用する
ことができる前記精製濃縮物及びその製造方法を提供す
ることを目的とする。As described above, the inventors of the present invention solid-liquid separate the barley shochu distillation residual liquid by-produced in the production of shochu using barley as a raw material to obtain a liquid component, and the liquid component is adsorbed using a synthetic adsorbent. A purified concentrate obtained by subjecting to a treatment to obtain an adsorption fraction and eluting the adsorption fraction with an alkali or ethanol is significantly more potent than the untreated barley shochu distillation residual liquid in suppressing the development of liver damage. It has been found that it has an action, that is, an action of strongly suppressing the onset of orotic acid-induced fatty liver and an action of strongly suppressing the onset of D-galactosamine-induced hepatitis. This discovery of barley shochu distillation residue is a new fact that has never been seen before, and a new barley shochu distillation residue that barley shochu distillation residue can be used as a food or medicine for the purpose of preventing liver damage. It creates various uses. An object of the present invention is to provide the above-mentioned purified concentrate which can be effectively used as a food or a medicine and a method for producing the same.

【００１０】上述したように、本発明により提供される
肝障害（オロチン酸誘発性脂肪肝及びD-ガラクトサミン
誘発性肝炎）の発症を抑制する作用を有する精製濃縮物
は、大麦を原料とする焼酎製造において副成する大麦焼
酎蒸留残液を固液分離して液体分を得、該液体分を合成
吸着剤を用いる吸着処理に付して吸着画分を得、該吸着
画分をアルカリ又はエタノールを用いて溶出することに
より分取した脱着画分からなるものである。そして本発
明により提供される該精製濃縮物は、食品或いは医薬と
して有効に使用することが出来るものである。As described above, the purified concentrate provided by the present invention, which has the action of suppressing the onset of liver damage (orotic acid-induced fatty liver and D-galactosamine-induced hepatitis), is a barley-based shochu. The barley shochu distillation residual liquid by-produced in the production is subjected to solid-liquid separation to obtain a liquid content, and the liquid content is subjected to an adsorption treatment using a synthetic adsorbent to obtain an adsorption fraction, and the adsorption fraction is alkali or ethanol. It is composed of a desorbed fraction separated by elution with. The purified concentrate provided by the present invention can be effectively used as food or medicine.

【００１１】本発明において使用する大麦焼酎蒸留残液
は、代表的には、大麦又は精白大麦を原料として大麦麹
及び蒸麦を製造し、得られた大麦麹及び蒸麦中に含まれ
るでんぷんを該大麦麹の麹により糖化し、それらを酵母
によるアルコール発酵に付して焼酎熟成もろみを得、得
られた焼酎熟成もろみを減圧蒸留又は常圧蒸留等の単式
蒸留装置を用いて蒸留する際に蒸留残渣として副成する
もの、即ち、大麦焼酎の蒸留残液を意味する。The barley shochu distillation residual liquid used in the present invention is typically produced from barley or refined barley as a raw material to prepare barley koji and steamed barley, and the starch contained in the obtained barley malt and steamed barley is typically used. When the barley koji is saccharified with koji and subjected to alcohol fermentation with yeast to obtain shochu aged moromi, when the obtained shochu aged moromi is distilled using a single distillation apparatus such as vacuum distillation or atmospheric distillation. It means a by-product as a distillation residue, that is, a distillation residual liquid of barley shochu.

【００１２】本発明において、大麦焼酎蒸留残液を得る
に際して、大麦焼酎の製造に用いる大麦麹は、通常の大
麦焼酎製造において行われている製麹条件で製造すれば
よく、用いる麹菌株としては、一般的に大麦焼酎製造で
使用する白麹菌（Aspergillus kawachii）が好ましい。
或いは泡盛製造で使用する黒麹菌（Aspergillus awamor
ii）及び清酒製造等で使用する黄麹(Aspergillus oryza
e）などのAspergillus属の菌株を用いることもできる。
また大麦焼酎の製造に用いる酵母は、一般的に焼酎製造
の際に使用する各種の焼酎醸造用酵母を使用することが
できる。In the present invention, when the barley shochu distillation residual liquid is obtained, the barley koji used in the production of barley shochu may be produced under the koji making conditions which are usually used in the production of barley shochu, and the koji mold strain to be used is In general, white koji mold (Aspergillus kawachii) used in barley shochu production is preferable.
Or Aspergillus awamor used in awamori manufacturing
ii) and yellow koji (Aspergillus oryza) used in sake production etc.
Strains of the genus Aspergillus such as e) can also be used.
As the yeast used for producing barley shochu, various kinds of yeast for shochu brewing generally used during production of shochu can be used.

【００１３】本発明において、大麦焼酎の製造における
蒸留工程で得られた大麦焼酎蒸留残液を固液分離して液
体分を得る第1の工程は、大麦焼酎蒸留残液から原料大
麦、あるいは大麦麹由来の水不溶性の発酵残渣等のSS分
を除去し、清澄液を得ることを目的として行うものであ
る。この第1の工程における当該固液分離は、スクリュ
ープレス方式やローラープレス方式の固液分離方法によ
り行うことができる。この他、ろ過圧搾式の固液分離機
を用いて予備分離を行い、次いで遠心分離機、ケイソウ
土ろ過装置、セラミックろ過装置、或いはろ過圧搾機等
を用いた方法により本固液分離処理を行ってもよい。第
1の工程で得られた前記液体分を合成吸着剤を用いる吸
着処理に付して吸着画分を得る第2の工程は、該液体分
に含まれる肝障害発症抑制作用を有する成分を該合成吸
着剤を用いて吸着分取することを目的として行うもので
ある。第2の工程で使用する合成吸着剤としては、芳香
族系、芳香族系修飾型、或いはメタクリル系の合成吸着
剤を用いることができる。そうした、合成吸着剤の好適
な具体例としては、オルガノ社製のアンバーライトXAD-
16、三菱化学社製のセパビーズSP850、及び同三菱化学
社製のダイヤイオンHP20等を挙げることができる。In the present invention, the first step of solid-liquid separating the barley shochu distillation residual liquid obtained in the distillation step in the production of barley shochu to obtain a liquid component is the raw barley shochu distillation residual liquid, or barley. The purpose is to obtain a clarified liquid by removing SS components such as water-insoluble fermentation residue derived from koji. The solid-liquid separation in the first step can be performed by a screw-press method or a roller-press method. In addition to this, preliminary separation is performed using a filtration press type solid-liquid separator, and then this solid-liquid separation process is performed by a method using a centrifuge, a diatomaceous earth filtration device, a ceramic filtration device, or a filtration press. May be. First
The second step of obtaining the adsorption fraction by subjecting the liquid component obtained in the step 1 to an adsorption treatment using a synthetic adsorbent, is to synthesize a component having a hepatic disorder development inhibitory action contained in the liquid component. This is performed for the purpose of adsorption and fractionation using an adsorbent. As the synthetic adsorbent used in the second step, an aromatic, aromatic modified, or methacrylic synthetic adsorbent can be used. As a specific example of such a synthetic adsorbent, Amberlite XAD- manufactured by Organo Co., Ltd.
16, Mitsubishi Chemical's SepaBeads SP850, Mitsubishi Chemical's Diaion HP20 and the like can be mentioned.

【００１４】また、第3の工程においては、第2の工程で
得られる吸着画分をエタノール又はアルカリを用いて溶
出することにより、肝障害発症抑制作用を有する画分を
得る。特に、アルカリを用いて溶出を行う場合には、該
アルカリの好適な具体例として，水酸化ナトリウム、及
び水酸化カリウム等を挙げることができる。こうしたア
ルカリを用いて合成吸着剤から溶出した吸着画分はナト
リウムイオンやカリウムイオンなどの陽イオンを含むこ
とから、さらにイオン交換処理に付すことができる。こ
のようなイオン交換処理は、陽イオン交換樹脂等を用い
て行うことができる。陽イオン交換樹脂として好適な具
体例としては、オルガノ社製の強酸性陽イオン交換樹脂
IR120や弱酸性陽イオン交換樹脂IRC50及びIRC76、さら
に三菱化学社製の強酸性陽イオン交換樹脂ダイヤイオン
SK1B、SK104、PK208や弱酸性陽イオン交換樹脂WK10、WK
40等を挙げることができる。また、上記アルカリを用い
て合成吸着剤から溶出した吸着画分は、塩酸、酢酸、ク
エン酸などの無機酸又は有機酸等を用いて中和処理に付
すこともでき、更に前記中和処理に付した後の吸着画分
を前記陽イオン交換樹脂を用いて脱塩処理に付すことも
できる。以下に本発明を完成するにあたり、本発明者ら
が行った実験について詳述する。In the third step, the adsorbed fraction obtained in the second step is eluted with ethanol or alkali to obtain a fraction having a hepatic disorder onset suppressing action. In particular, when elution is carried out using an alkali, preferred specific examples of the alkali include sodium hydroxide and potassium hydroxide. Since the adsorption fraction eluted from the synthetic adsorbent using such an alkali contains cations such as sodium ions and potassium ions, it can be further subjected to an ion exchange treatment. Such ion exchange treatment can be performed using a cation exchange resin or the like. Specific examples of suitable cation exchange resins include strong acid cation exchange resins manufactured by Organo Corporation.
IR120, weak acid cation exchange resins IRC50 and IRC76, and Mitsubishi Chemical's strong acid cation exchange resin Diaion
SK1B, SK104, PK208 and weak acid cation exchange resins WK10, WK
40 etc. can be mentioned. Further, the adsorption fraction eluted from the synthetic adsorbent using the above alkali can be subjected to a neutralization treatment using an inorganic acid such as hydrochloric acid, acetic acid or citric acid, or an organic acid, and further to the neutralization treatment. The adsorbed fraction after application can be subjected to desalting treatment using the cation exchange resin. The experiments conducted by the present inventors in completing the present invention will be described in detail below.

【００１５】本発明者らは、上述した報告に鑑みて、大
麦焼酎蒸留残液がオロチン酸誘発性脂肪肝に対する発症
抑制作用を有することから、該大麦焼酎蒸留残液を遠心
分離に付して上清の液体分と沈殿の固体分とを分取し、
該液体分と該固体分をそれぞれ別々に凍結乾燥に付して
液体分の凍結乾燥粉末及び固体分の凍結乾燥粉末を得、
得られた液体分の凍結乾燥粉末及び固体分の凍結乾燥粉
末が、オロチン酸誘発性脂肪肝に対する発症抑制作用を
有するか否かを明らかにするために以下の実験1-Aを行
った。In view of the above report, the present inventors have considered that the barley shochu distillation residual liquid has a suppressive effect on orotate-induced fatty liver, and therefore the barley shochu distillation residual liquid was subjected to centrifugation. Separate the liquid content of the supernatant and the solid content of the precipitate,
The liquid component and the solid component are separately subjected to freeze-drying to obtain a freeze-dried powder of the liquid component and a freeze-dried powder of the solid component,
The following Experiment 1-A was performed in order to clarify whether the obtained freeze-dried powder of liquid and freeze-dried powder of solid have a suppressive effect on orotate-induced fatty liver.

【００１６】以下の実験に供する目的で大麦焼酎の製造
を行った。原料としては、大麦（70%精白）を用いた。Barley shochu was produced for the purpose of carrying out the following experiment. Barley (70% polished) was used as a raw material.

【麹の製造】大麦を40%（w/w）吸水させ、40分間蒸した
後、40℃まで放冷し、大麦トンあたり1kgの種麹（白麹
菌）を接種し、38℃、RH95%で24時間、32℃、RH92%で20
時間保持することにより、大麦麹を製造した。[Manufacture of koji] 40% (w / w) of barley is absorbed in water, steamed for 40 minutes, allowed to cool to 40 ° C, and inoculated with 1 kg of seed koji (white koji mold) per ton of barley, 38 ° C, RH 95% 24 hours at 32 ℃, RH 92% at 20
The barley koji was produced by holding for a time.

【蒸麦の製造】大麦を40%（w/w）吸水させ、40分間蒸し
た後、40℃まで放冷することにより、蒸麦を製造した。[Manufacture of Steamed Barley] Steamed barley was manufactured by allowing 40% (w / w) of barley to absorb water, steaming it for 40 minutes, and allowing it to cool to 40 ° C.

【００１７】[0017]

【大麦焼酎及び大麦焼酎蒸留残液の製造】1次仕込みで
は前述の方法で製造した大麦麹（大麦として3トン）
に、水3.6キロリットル及び酵母として焼酎酵母の培養
菌体1kg（湿重量）を加えて1次もろみを得、得られた1
次もろみを5日間の発酵（1段目の発酵）に付した。次い
で、2次仕込みでは、上記1段目の発酵を終えた1次もろ
みに、水11.4キロリットル、前述の方法で製造した蒸麦
（大麦として7トン）を加えて11日間の発酵（2段目の発
酵）に付した。発酵温度は1次仕込み、2次仕込みとも25
℃とした。上記2段目の発酵を終えた2次もろみを常法に
より単式蒸留に付し、大麦焼酎10キロリットルと大麦焼
酎蒸留残液15キロリットルを得た。[Manufacture of barley shochu and barley shochu distillation residual liquid] Barley malt (3 tons as barley) manufactured by the above-mentioned method in the primary charge
To this, 3.6 kiloliters of water and 1 kg (wet weight) of culture of shochu yeast as yeast were added to obtain a primary mash.
Next moromi was subjected to fermentation for 5 days (first stage fermentation). Next, in the secondary preparation, 11.4 kiloliters of water and steamed barley (7 tons as barley) produced by the above-mentioned method were added to the primary moromi that had undergone the first stage fermentation, and the fermentation was continued for 11 days (2 stages). Fermentation of eyes). Fermentation temperature is 25 for both primary and secondary preparations.
℃ was made. The second moromi, which had undergone the second-stage fermentation, was subjected to simple distillation by a conventional method to obtain 10 kiloliters of barley shochu and 15 kiloliters of the barley shochu distillation residual liquid.

【００１８】[0018]

【実験1-A】4週齢Wistar系雄性ラット（日本SLC）を1群
6匹として、一般的に栄養学的実験を行う際の標準食と
して使用する基本食を摂取させる基本食群、該基本食に
脂肪肝を人為的に発現させる際に一般的に用いられる1%
オロチン酸を混合した対照食を与える対照食群、該対照
食に前記大麦焼酎蒸留残液の凍結乾燥物10%を混合した
試験食Aを摂取させる試験食A群、該対照食に該大麦焼酎
蒸留残液を遠心分離して得られる液体分の凍結乾燥物を
7.3%含む試験食Bを摂取させる試験食B群、及び該対照食
に該大麦焼酎蒸留残液を遠心分離して得られる固体分の
凍結乾燥物を2.7%含む試験食Cを摂取させる試験食C群、
の5群に分け、それぞれの群に表1に示す組成の飼料を水
道水と共に14日間自由摂取させて飼育した。なお、上記
試験食B群及び試験食C群において、該大麦焼酎蒸留残液
を遠心分離して得た液体分及び固体分のそれぞれの凍結
乾燥物の各試料中における含量は、試験食A群において
飼料に混合した大麦焼酎蒸留残液の凍結乾燥物10%中の
それぞれの含量に相当する量とした。飼育期間終了後、
14日間飼育後の体重増加量、14日間の飼料摂取量を測定
し、ラットを解剖後、心臓から血液を採取し、肝臓を摘
出した。採取した血液は遠心分離して血清を得、得られ
た血清について、常法に従って、血清総コレステロール
濃度、血清HDL-コレステロール濃度、血清トリグリセリ
ド濃度、及び血清リン脂質濃度を測定し、摘出した肝臓
については、その重量、肝臓総脂質濃度、肝臓コレステ
ロール濃度、肝臓トリグリセリド濃度、及び肝臓リン脂
質濃度を測定した。[Experiment 1-A] 1 group of 4-week-old male Wistar rats (Japan SLC)
As 6 animals, a basic diet group that receives a basic diet that is generally used as a standard diet when performing a nutritional experiment, and 1% that is generally used when artificially expressing fatty liver in the basic diet.
A control diet group that gives a control diet mixed with orotic acid, a test diet A group that ingests a test diet A in which the lyophilized product of the barley shochu distillation residual liquid 10% is mixed with the control diet, the barley shochu is added to the control diet. The lyophilized product of the liquid component obtained by centrifuging the distillation residual liquid
Test food group B containing 7.3% of test food B, and test food containing test food C containing 2.7% of freeze-dried solids obtained by centrifuging the barley shochu distillation residual liquid to the control food. Group C,
Were divided into 5 groups, and each group was bred by freely ingesting the feed having the composition shown in Table 1 together with tap water for 14 days. In the test food B group and the test food C group, the content in each sample of the lyophilized product of the liquid and solid components obtained by centrifugation of the barley shochu distillation residual liquid, the test food A group In 10% of the freeze-dried product of the barley shochu distillation residue mixed with the feed, the amount was set to correspond to each content. After the breeding period,
The amount of weight gain after feeding for 14 days and the amount of feed intake for 14 days were measured, the rat was dissected, blood was collected from the heart, and the liver was excised. The collected blood was centrifuged to obtain serum, and the serum obtained was measured for serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration according to a conventional method, and the excised liver was extracted. Measured their weight, liver total lipid concentration, liver cholesterol concentration, liver triglyceride concentration, and liver phospholipid concentration.

【００１９】血清総コレステロール濃度、血清HDL-コレ
ステロール濃度、血清トリグリセリド濃度、血清リン脂
質濃度肝臓重量、肝臓総脂質濃度、肝臓コレステロール
濃度、肝臓トリグリセリド濃度、肝臓リン脂質濃度、及
び肝臓重量の測定結果を表2に示す。表2に示す結果から
以下の事実が判明した。即ち、肝臓重量は対照食群と試
験食C群で増加し、試験食A群及び試験食B群では基本食
群の示す正常値に近似した値を示した。肝臓総脂質濃
度、肝臓コレステロール濃度、及び肝臓トリグリセリド
濃度は、対照食群と試験食C群では顕著に増加したが、
試験食A群及び試験食B群では基本食群の示す正常値に近
似した値を示した。一方、血清総コレステロール濃度、
血清HDL-コレステロール濃度、血清トリグリセリド濃
度、及び血清リン脂質濃度は、対照食群と試験食C群で
は低下したのに対して、試験食A群及び試験食B群は基本
食群の示す正常値に近似した値を示した。即ち、脂肪肝
を人為的に発症させるオロチン酸を含む対照食に大麦焼
酎蒸留残液の凍結乾燥物を混合した試験食A群と該対照
食に該大麦焼酎蒸留残液を遠心分離して得た液体分の凍
結乾燥物を混合した試験食B群においてはオロチン酸誘
発性脂肪肝の発症が顕著に抑制された。一方、該対照食
に該大麦焼酎蒸留残液を遠心分離して得た固体分の凍結
乾燥物を混合した試験食C群においては脂肪肝の発症が
全く抑制されることなく、該オロチン酸誘発性脂肪肝が
顕著に発症することが明らかとなった。以上の実験結果
から、大麦焼酎蒸留残液が有するオロチン酸誘発性脂肪
肝の発症抑制に寄与する成分は、その液体分中に含まれ
ていることが判明した。Serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, serum phospholipid concentration liver weight, total liver lipid concentration, liver cholesterol concentration, liver triglyceride concentration, liver phospholipid concentration, and liver weight measurement results Shown in Table 2. The following facts were found from the results shown in Table 2. That is, the liver weight increased in the control diet group and the test diet C group, and the test diet A group and the test diet B group showed values close to the normal values shown in the basic diet group. Liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration were significantly increased in the control diet group and the test diet C group,
The values of the test diet A group and the test diet B group were close to the normal values of the basic diet group. On the other hand, serum total cholesterol concentration,
Serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration decreased in the control diet group and the test diet C group, whereas the test diet group A and the test diet group B showed normal values in the basic diet group. The value was approximated to. That is, a control diet containing orotic acid that artificially develops fatty liver was mixed with a freeze-dried product of barley shochu distillation residual liquid to a test diet A group and the control diet to obtain the barley shochu distillation residual liquid by centrifugation. The occurrence of orotate-induced fatty liver was remarkably suppressed in the test diet group B in which the lyophilized product of the liquid content was mixed. On the other hand, in the control diet group C, in which the freeze-dried solid fraction obtained by centrifugation of the barley shochu distillation residual liquid was mixed with the control diet, the development of fatty liver was not suppressed at all, and the orotic acid induction It was clarified that hepatic steatosis was prominently developed. From the above experimental results, it was revealed that the components of the barley shochu distillation residual liquid that contribute to the suppression of the onset of orotic acid-induced fatty liver are contained in the liquid component.

【００２０】そこで、大麦焼酎蒸留残液を固液分離して
得られた液体分に含まれるオロチン酸誘発性脂肪肝の発
症抑制及びD-ガラクトサミン誘発性肝炎の発症抑制に寄
与する成分を分取する目的で、以下の実験2-A、及び実
験2-Bを行った。即ち、大麦焼酎蒸留残液から得られた
前記液体分を合成吸着剤に付すことにより吸着画分と非
吸着画分に分画し、それぞれの画分のオロチン酸誘発性
脂肪肝に対する発症抑制作用及びD-ガラクトサミン誘発
性肝炎に対する発症抑制作用を検討した。Therefore, the components that contribute to the suppression of the development of orotate-induced fatty liver and the suppression of the development of D-galactosamine-induced hepatitis contained in the liquid obtained by solid-liquid separation of the barley shochu distillation residual liquid are collected. The following Experiment 2-A and Experiment 2-B were performed for the purpose of That is, the liquid fraction obtained from the barley shochu distillation residual liquid was fractionated into an adsorbed fraction and a non-adsorbed fraction by subjecting it to a synthetic adsorbent, and the onset inhibitory effect on the orotate-induced fatty liver of each fraction. And the inhibitory effect on the onset of hepatitis induced by D-galactosamine was examined.

【００２１】[0021]

【大麦焼酎蒸留残液液体分からの合成吸着剤吸着画分の
取得】以下の実験2-A及び実験2-Bに供する目的で、前記
大麦焼酎蒸留残液から得た液体分を次に示す方法に従っ
て合成吸着剤吸着画分と合成吸着剤非吸着画分に分画し
た。即ち、大麦焼酎蒸留残液を8000rpm,10minの条件で
遠心分離して大麦焼酎蒸留残液の液体分を得、得られた
液体分25Lと脱イオン水10Lをこの順番にオルガノ社製の
合成吸着剤アンバーライトXAD-16を充填したカラム（樹
脂容量10L）に接触させることにより、該カラムに対し
て非吸着性を示す非吸着画分からなる溶出液（a）を得
た。該非吸着画分からなる溶出液（a）を凍結乾燥に付
し、非吸着画分の凍結乾燥物（a'）2400gを得、該凍結
乾燥物（a'）を以下の実験2-A及び実験2-Bに用いた。さ
らに該カラムに1(wt/vol)%の 水酸化ナトリウム溶液10L
と脱イオン水10Lをこの順番に接触させることにより該
カラムに対して吸着性を示す吸着画分を含有する溶出液
(b)20Lを得た。さらに該溶出液(b)20Lをオルガノ社製強
酸性陽イオン交換樹脂IR-120Bを充填したカラム（樹脂
容量10L）に接触させた後に凍結乾燥に付すことによ
り、ナトリウムイオンを除去した吸着画分の凍結乾燥物
（b'）270gを得、該凍結乾燥物（b'）を以下の実験2-A
及び実験2-Bに用いた。[Acquisition of Synthetic Adsorbent Adsorption Fraction from Barley Shochu Distillation Liquid Residue] For the purpose of performing the following Experiment 2-A and Experiment 2-B, the following method is used for the liquid component obtained from the barley shochu distilling liquid The synthetic adsorbent-adsorbed fraction and the synthetic adsorbent-non-adsorbed fraction were separated according to the above procedure. That is, the barley shochu distillation residual liquid was centrifuged at 8000 rpm for 10 min to obtain a liquid content of the barley shochu distillation residual liquid, and the obtained liquid content 25 L and deionized water 10 L were synthesized in this order by Organo By contacting with a column packed with the agent Amberlite XAD-16 (resin capacity 10 L), an eluate (a) consisting of a non-adsorbed fraction showing non-adsorbability to the column was obtained. The eluate (a) consisting of the non-adsorbed fraction was subjected to freeze-drying to obtain 2400 g of the freeze-dried product (a ') of the non-adsorbed fraction. The freeze-dried product (a') was subjected to the following Experiment 2-A and experiment. Used for 2-B. Furthermore, 10 L of 1 (wt / vol)% sodium hydroxide solution was applied to the column.
An eluate containing an adsorption fraction that exhibits adsorption to the column by contacting with 10 L of deionized water in this order
(b) 20 L was obtained. Further, 20 L of the eluate (b) was brought into contact with a column (resin volume: 10 L) packed with a strong acid cation exchange resin IR-120B manufactured by Organo Co., Ltd., followed by freeze-drying to remove an adsorption fraction from which sodium ions were removed. 270 g of the lyophilized product (b ′) of
And used in Experiment 2-B.

【００２２】[0022]

【実験2-A】本実験は、上記吸着画分(b)の凍結乾燥物
（b'）及び上記非吸着画分(a)の凍結乾燥物（a'）を用
いて、それぞれのオロチン酸誘発性脂肪肝に対する発症
抑制作用を調べる目的で行った。即ち、4週齢Wistar系
雄性ラット（日本SLC）を1群6匹として、一般的に栄養
学的実験を行う際の標準食として使用する基本食を摂取
させる基本食群、該基本食に脂肪肝を人為的に発現させ
る際に一般的に用いられる1%オロチン酸を混合した対照
食を与える対照食群、該対照食に前記吸着画分の凍結乾
燥物（b'）を10重量%含む試験食Aを摂取させる試験食A
群、及び該対照食に前記非吸着画分の凍結乾燥物（a'）
10重量%を混合した試験食Bを摂取させる試験食B群の4群
に分け、それぞれの群に表3に示す組成の飼料を水道水
と共に14日間自由摂取させて飼育した。飼育期間終了
後、14日間飼育後の体重増加量、14日間の飼料摂取量を
測定し、ラットを解剖後、心臓から血液を採取し、肝臓
を摘出した。採取した血液は遠心分離して血清を得、得
られた血清について、常法に従って、血清総コレステロ
ール濃度、血清HDL-コレステロール濃度、血清トリグリ
セリド濃度、及び血清リン脂質濃度を測定し、摘出した
肝臓については、その重量、肝臓総脂質濃度、肝臓コレ
ステロール濃度、肝臓トリグリセリド濃度、及び肝臓リ
ン脂質濃度を測定した。[Experiment 2-A] This experiment was performed using the lyophilized product (b ') of the adsorbed fraction (b) and the lyophilized product (a') of the non-adsorbed fraction (a). The purpose of this study was to investigate the onset-suppressing effect on induced fatty liver. That is, a group of 6 4-week-old Wistar male rats (Japan SLC) is used as a standard diet for nutritional experiments. A control diet group that gives a control diet mixed with 1% orotic acid, which is generally used when artificially expressing the liver, and the control diet contains 10% by weight of the lyophilized product (b ′) of the adsorption fraction. Test food A to ingest test food A
Lyophilized product (a ') of the non-adsorbed fraction in the group and the control food
The test diet B group containing 10% by weight of the test diet B was divided into 4 groups, and each group was fed with the feed having the composition shown in Table 3 freely for 14 days together with tap water. After the breeding period was completed, the amount of weight gain after breeding for 14 days and the feed intake for 14 days were measured, the rat was dissected, blood was collected from the heart, and the liver was excised. The collected blood was centrifuged to obtain serum, and the serum thus obtained was measured for serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration according to a conventional method, and the excised liver was extracted. Measured their weight, liver total lipid concentration, liver cholesterol concentration, liver triglyceride concentration, and liver phospholipid concentration.

【００２３】血清総コレステロール濃度、血清HDL-コレ
ステロール濃度、血清トリグリセリド濃度、血清リン脂
質濃度肝臓重量、肝臓総脂質濃度、肝臓コレステロール
濃度、肝臓トリグリセリド濃度、肝臓リン脂質濃度、及
び肝臓重量の測定結果を表4に示す。表4に示す結果から
以下の事実が判明した。肝臓重量は対照食群及び試験食
B群で増加し、試験食A群では基本食の正常値と実質的に
同等の値を示した。肝臓総脂質濃度、肝臓コレステロー
ル濃度、及び肝臓トリグリセリド濃度は、対照食群及び
試験食B群では顕著に増加したが、試験食A群では基本食
の正常値と実質的に同等の値，又は該正常値よりも低い
値を示した。一方、血清総コレステロール濃度、血清HD
L-コレステロール濃度、血清トリグリセリド濃度、及び
血清リン脂質濃度は、対照食群及び試験食B群が低下し
たのに対して、試験食A群は基本食の正常値と実質的に
同等の値を示した。即ち、脂肪肝を人為的に発現させる
オロチン酸を含む対照食に前記非吸着画分の凍結乾燥物
（a'）を混合した試験食B群においてはオロチン酸誘発
性脂肪肝の発症が全く抑制されなかった。一方、脂肪肝
を人為的に発症させるオロチン酸を含む対照食に該前記
吸着画分の凍結乾燥物（b'）を混合した試験食A群にお
いてはオロチン酸誘発性脂肪肝の発症が完全に抑制され
た。以上の実験結果から、大麦焼酎蒸留残液を固液分離
することにより得られた液体分に含まれるオロチン酸誘
発性脂肪肝の発症抑制に寄与する成分は、合成吸着剤に
対する吸着画分(b)に含まれていることが判明した。Serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, serum phospholipid concentration liver weight, total liver lipid concentration, liver cholesterol concentration, liver triglyceride concentration, liver phospholipid concentration, and liver weight measurement results Shown in Table 4. The following facts were found from the results shown in Table 4. Liver weight is the control diet and test diet
It increased in the B group, and the test diet A group showed a value substantially equivalent to the normal value of the basic diet. The liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration were significantly increased in the control diet group and the test diet B group, but in the test diet group A, a value substantially equivalent to the normal value of the basic diet, or the The value was lower than the normal value. On the other hand, serum total cholesterol concentration, serum HD
L-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration decreased in the control diet group and the test diet B group, whereas the test diet A group had values substantially equivalent to the normal values of the basic diet. Indicated. That is, in the test diet group B in which the freeze-dried product (a ') of the non-adsorbed fraction was mixed with a control diet containing orotic acid that artificially expresses fatty liver, the onset of orotic acid-induced fatty liver was completely suppressed. Was not done. On the other hand, in the test diet group A in which the freeze-dried product (b ') of the adsorption fraction was mixed with the control diet containing orotic acid that artificially develops fatty liver, the onset of orotic acid-induced fatty liver was completely observed. Suppressed From the above experimental results, the components that contribute to the suppression of the development of orotate-induced fatty liver contained in the liquid obtained by solid-liquid separation of the barley shochu distillation residual liquid, the adsorption fraction to the synthetic adsorbent (b ) Has been found to be included.

【００２４】上記吸着画分の凍結乾燥物（b'）及び上記
非吸着画分の凍結乾燥物（a'）を用いて、それぞれのD-
ガラクトサミン誘発性肝炎に対する発症抑制作用を調べ
る目的で、以下の実験2-Bを行った。Using the lyophilized product (b ') of the adsorbed fraction and the lyophilized product (a') of the non-adsorbed fraction, the respective D-
The following Experiment 2-B was conducted for the purpose of investigating the suppressive effect on the onset of galactosamine-induced hepatitis.

【００２５】[0025]

【実験2-B】5週令のWistar系雄性ラットを1群9匹とし
て、対照食を摂取させる対照食群、該対照食に含まれる
成分の一部を前記吸着画分の凍結乾燥物（b'）2重量%で
代替した試験食Aを摂取させる試験食A群、該対照食に含
まれる成分の一部を前記非吸着画分の凍結乾燥物（a'）
2重量%で代替した試験食Bを摂取させる試験食B群、及び
該対照食に含まれる成分の一部を上記大麦焼酎蒸留残液
の液体分の凍結乾燥物2重量%で代替した試験食Cを摂取
させる試験食C群、の４群に分け、それぞれの群に表5に
示す組成の飼料を水道水と共に15日間自由摂取させて飼
育した。実験食投与14日目にD-ガラクトサミンを350mg/
kg体重となるようにラットの腹腔内に投与し、22時間後
にラットを屠殺後、血液を採取し、これを遠心分離して
血清を得、得られた血清について、血清中のGOT及びGPT
を測定するとともに、肝臓の病理組織学的検索を行っ
た。[Experiment 2-B] A group of 9 Wistar male rats aged 5 weeks was used as a control diet, a control diet group was fed a control diet, and some of the components contained in the control diet were lyophilized from the adsorbed fraction ( b ') A test food group A in which the test food A substituted with 2% by weight is ingested, and a part of the components contained in the control food is a lyophilized product (a') of the non-adsorbed fraction.
Test food B group ingesting test food B replaced by 2% by weight, and a test food in which a part of the components contained in the control food was replaced by a freeze-dried product 2% by weight of the liquid content of the barley shochu distillation residual liquid It was divided into four groups, ie, a test food group C in which C was ingested, and each group was bred by freely ingesting the feed having the composition shown in Table 5 together with tap water for 15 days. On the 14th day of administration of the experimental diet, 350 mg / D-galactosamine
It was intraperitoneally administered to a rat so that the body weight became kg, and after 22 hours, the rat was sacrificed, blood was collected, and the blood was collected by centrifugation to obtain serum. GOT and GPT in the serum were obtained.
Was measured and a histopathological search of the liver was performed.

【００２６】血清中のGOT及びGPTの測定結果を表6に示
す。表6に示す結果から以下の事実が判明した。GOT及び
GPTの値は、試験食A群が、対照食群に比べて極めて顕著
に低下した。一方、試験食B群および試験食C群において
は、GOT及びGPTの値は、対照食群に比べて低下したもの
の、その低下の程度は前記試験食A群と比べて明らかに
小さいものであった。肝臓の病理組織学的検索では、対
照食群の肝小葉中心体に強くみられた肝細胞の変成・壊
死が試験食A群ではほとんど認められなかった。即ち、
上記吸着画分の凍結乾燥物（b'）を混合した試験食A群
においては、D-ガラクトサミン誘発性肝炎の発症が顕著
に抑制された。この結果から、大麦焼酎蒸留残液の液体
分を合成吸着剤に付すことにより得られる吸着画分
（ｂ）は、大麦焼酎蒸留残液の液体分に比べてD-ガラク
トサミン誘発性肝炎の発症抑制作用が極めて強力である
ことが判明した。Table 6 shows the measurement results of GOT and GPT in serum. The following facts were found from the results shown in Table 6. GOT and
The GPT value was significantly lower in the test diet group A than in the control diet group. On the other hand, in the test diet B group and the test diet C group, the GOT and GPT values were lower than those in the control diet group, but the extent of the reduction was clearly smaller than that in the test diet group A. It was In the histopathological examination of the liver, hepatocyte degeneration and necrosis, which were strongly observed in the centrilobular body of the liver of the control diet group, were hardly observed in the test diet group A. That is,
In the test diet group A in which the freeze-dried product (b ′) of the adsorbed fraction was mixed, the onset of D-galactosamine-induced hepatitis was significantly suppressed. From these results, the adsorption fraction (b) obtained by adding the liquid content of the barley shochu distillation residual liquid to the synthetic adsorbent was found to suppress the onset of D-galactosamine-induced hepatitis as compared with the liquid content of the barley shochu distillation residual liquid. The action was found to be extremely strong.

【００２７】以上の実験結果から、大麦焼酎蒸留残液の
液体分に含まれる肝障害発症抑制作用、即ち、オロチン
酸誘発性脂肪肝及びD-ガラクトサミン誘発性肝炎のそれ
ぞれに対する発症抑制作用に寄与する成分は、大麦焼酎
蒸留残液の液体分を合成吸着剤に付すことにより得られ
る吸着画分に濃縮されて含まれていることが判明した。From the above experimental results, it contributes to the inhibitory effect on the development of liver damage contained in the liquid fraction of the barley shochu distillation residual liquid, that is, the inhibitory effect on the development of orotic acid-induced fatty liver and D-galactosamine-induced hepatitis. It was found that the components were concentrated and contained in the adsorption fraction obtained by subjecting the liquid content of the barley shochu distillation residual liquid to a synthetic adsorbent.

【００２８】そこで肝障害発症抑制作用、即ち、オロチ
ン酸誘発性脂肪肝に対する発症抑制作用及びD-ガラクト
サミン誘発性肝炎に対する発症抑制作用を有することが
判明した大麦焼酎蒸留残液の液体分の合成吸着剤吸着画
分の成分組成を下記の方法により測定した。Therefore, it has been found that it has an inhibitory effect on the onset of liver damage, that is, an inhibitory effect on orotate-induced fatty liver and an inhibitory effect on D-galactosamine-induced hepatitis. The component composition of the agent adsorption fraction was measured by the following method.

【合成吸着剤吸着画分の成分組成の分析】前記合成吸着
剤吸着画分の成分組成の分析を行った。即ち、[Analysis of Component Composition of Synthetic Adsorbent Adsorption Fraction] The composition of the synthetic adsorbent adsorption fraction was analyzed. That is,

【００１７】に記載した「大麦焼酎及び大麦焼酎蒸留残
液の製造」の方法を複数回行って、ロットを異にする複
数の大麦焼酎蒸留残液を用意した。それぞれの大麦焼酎
蒸留残液を、The method of "manufacturing barley shochu and barley shochu distillation residual liquid" described in 1) was carried out a plurality of times to prepare a plurality of barley shochu distillation residual liquids of different lots. Each barley shochu distillation residual liquid,

【００２１】に記載した「大麦焼酎蒸留残液液体分から
の合成吸着剤吸着画分の取得」で採用したのと同様にし
て遠心分離して大麦焼酎蒸留残液の液体分を得、得られ
た液体分25Lと脱イオン水10Lをこの順番にオルガノ社製
の合成吸着剤アンバーライトXAD-16を充填したカラム
（樹脂容量10L）に接触させ、該カラムに吸着した吸着
画分を溶出することにより合成吸着剤吸着画分からなる
分析用試料を得た。この様にして、複数種の分析用試料
を作製した。夫々の合成吸着剤吸着画分からなる分析用
試料のタンパク質、糖組成、ポリフェノール及び有機酸
組成を測定した。タンパク質はケルダール法により、糖
組成は塩酸加水分解によるHPLC法により、ポリフェノー
ルはFolin-Ciocalteu 法により、有機酸組成はHPLC法に
よりそれぞれ測定した。前記合成吸着剤吸着画分の成分
組成（乾燥重量に基づく）の分析結果を表7に示す。表7
に示した結果から明らかなように、前記合成吸着剤吸着
画分は、粗タンパク４０乃至６０重量%、ポリフェノー
ル７乃至１２重量%、多糖類５乃至１０重量%（糖組成：
グルコース０乃至２重量%、キシロース３乃至５重量%、
及びアラビノース２乃至５重量%）、有機酸４乃至１０
重量% (リンゴ酸１乃至３重量%、クエン酸２乃至４重
量%、コハク酸０乃至１重量%、乳酸０乃至６重量%、及
び酢酸０乃至１重量%)、及び遊離糖類0乃至２重量%（マ
ルトース０乃至１重量%、キシロース０乃至１重量%、ア
ラビノース０乃至１重量%、及びグルコース０乃至１重
量%、）を含有することが明らかとなった。尚、上記分
析用試料の作製の手法を上記合成吸着剤アンバーライト
XAD-16以外の合成吸着剤用いて行い、上記複数種の大麦
焼酎蒸留残液の液体分の夫々について合成吸着剤吸着画
分からなる分析用試料を得、得られた分析用試料につい
て上述したのと同様にして分析を行ったところ、表７に
示すのと実質的に同等の結果が得られた。The liquid content of the barley shochu distillation residual liquid was obtained by centrifugation in the same manner as in "Acquisition of the synthetic adsorbent adsorption fraction from the barley shochu distillation residual liquid liquid". By contacting 25 L of liquid and 10 L of deionized water in this order with a column (resin capacity 10 L) packed with synthetic adsorbent Amberlite XAD-16 manufactured by Organo Co., and adsorbing the adsorbed fraction adsorbed on the column An analytical sample consisting of the adsorbed fraction of the synthetic adsorbent was obtained. In this way, plural kinds of analytical samples were prepared. The protein, sugar composition, polyphenol composition and organic acid composition of the analytical sample composed of the respective adsorbed fractions of the synthetic adsorbent were measured. Protein was measured by the Kjeldahl method, sugar composition was measured by the HPLC method using hydrochloric acid hydrolysis, polyphenol was measured by the Folin-Ciocalteu method, and organic acid composition was measured by the HPLC method. Table 7 shows the analysis results of the component composition (based on dry weight) of the synthetic adsorbent adsorption fraction. Table 7
As is clear from the results shown in the above, the synthetic adsorbent adsorption fraction contained 40 to 60% by weight of crude protein, 7 to 12% by weight of polyphenol, 5 to 10% by weight of polysaccharide (sugar composition:
Glucose 0 to 2% by weight, xylose 3 to 5% by weight,
And arabinose 2 to 5% by weight), organic acid 4 to 10
% By weight (1 to 3% by weight malic acid, 2 to 4% by weight citric acid, 0 to 1% by weight succinic acid, 0 to 6% by weight lactic acid, and 0 to 1% by weight acetic acid) and 0 to 2% by weight free sugars % (Maltose 0 to 1% by weight, xylose 0 to 1% by weight, arabinose 0 to 1% by weight, and glucose 0 to 1% by weight). In addition, the synthetic adsorbent Amberlite was used as the method for preparing the sample for analysis.
Performed using a synthetic adsorbent other than XAD-16, to obtain an analytical sample consisting of a synthetic adsorbent adsorption fraction for each of the liquid components of the above-mentioned plurality of barley shochu distillation residual liquids, the obtained analytical sample was described above. When analyzed in the same manner as above, the results substantially equivalent to those shown in Table 7 were obtained.

【００２９】以上のことから、本発明において大麦焼酎
蒸留残液の液体分、即ち大麦焼酎蒸留残液を固液分離し
て得られた液体分を吸着剤処理に付すことにより得られ
る吸着画分からなる肝障害発症抑制作用、即ち、オロチ
ン酸誘発性脂肪肝に対する発症抑制及びD-ガラクトサミ
ン誘発性肝炎に対する発症抑制作用を有する精製濃縮物
は、粗タンパク含量が高く、さらにポリフェノール、多
糖類、有機酸、及び遊離糖類を含有することが判明し
た。From the above, from the adsorption fraction obtained by subjecting the liquid component of the barley shochu distillation residual liquid in the present invention, that is, the liquid component obtained by solid-liquid separation of the barley shochu distillation residual liquid, to the adsorbent treatment A liver concentrate onset inhibitory effect, ie, a purified concentrate having an onset inhibitory effect on orotate-induced fatty liver and an onset inhibitory effect on D-galactosamine-induced hepatitis has a high crude protein content, and further polyphenols, polysaccharides, organic acids , And was found to contain free sugars.

【発明の実施の形態】DETAILED DESCRIPTION OF THE INVENTION

【００３０】[0030]

【実施例】以下に実施例を挙げて本発明を具体的に説明
するが，本発明はこれらの実施例によって何ら限定され
るものではない。EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.

【００３１】以下の実施例に供する目的で大麦焼酎の製
造を行った。原料としては、大麦（70%精白）を用い
た。Barley shochu was produced for the purpose of use in the following examples. Barley (70% polished) was used as a raw material.

【麹の製造】大麦を40%（w/w）吸水させ、40分間蒸した
後、40℃まで放冷し、大麦トンあたり1kgの種麹（白麹
菌）を接種し、38℃、RH95%で24時間、32℃、RH92%で20
時間保持することにより、大麦麹を製造した。[Manufacture of koji] 40% (w / w) of barley is absorbed in water, steamed for 40 minutes, allowed to cool to 40 ° C, and inoculated with 1 kg of seed koji (white koji mold) per ton of barley, 38 ° C, RH 95% 24 hours at 32 ℃, RH 92% at 20
The barley koji was produced by holding for a time.

【蒸麦の製造】大麦を40%（w/w）吸水させ、40分間蒸し
た後、40℃まで放冷することにより、蒸麦を製造した。[Manufacture of Steamed Barley] Steamed barley was manufactured by allowing 40% (w / w) of barley to absorb water, steaming it for 40 minutes, and allowing it to cool to 40 ° C.

【００３２】[0032]

【大麦焼酎及び大麦焼酎蒸留残液の製造】1次仕込みで
は前述の方法で製造した大麦麹（大麦として3トン）
に、水3.6キロリットル及び酵母として焼酎酵母の培養
菌体1kg（湿重量）を加えて1次もろみを得、得られた1
次もろみを5日間の発酵（1段目の発酵）に付した。次い
で、2次仕込みでは、上記1段目の発酵を終えた1次もろ
みに、水11.4キロリットル、前述の方法で製造した蒸麦
（大麦として7トン）を加えて11日間の発酵（2段目の発
酵）に付した。発酵温度は1次仕込み、2次仕込みとも25
℃とした。上記2段目の発酵を終えた2次もろみを常法に
より単式蒸留に付し、大麦焼酎10キロリットルと大麦焼
酎蒸留残液15キロリットルを得た。該大麦焼酎蒸留残液
を以下の実施例に用いた。[Manufacture of barley shochu and barley shochu distillation residual liquid] Barley malt (3 tons as barley) manufactured by the above-mentioned method in the primary charge
To this, 3.6 kiloliters of water and 1 kg (wet weight) of culture of shochu yeast as yeast were added to obtain a primary mash.
Next moromi was subjected to fermentation for 5 days (first stage fermentation). Next, in the secondary preparation, 11.4 kiloliters of water and steamed barley (7 tons as barley) produced by the above-mentioned method were added to the primary moromi that had undergone the first stage fermentation, and the fermentation was continued for 11 days (2 stages). Fermentation of eyes). Fermentation temperature is 25 for both primary and secondary preparations.
℃ was made. The second moromi, which had undergone the second-stage fermentation, was subjected to simple distillation by a conventional method to obtain 10 kiloliters of barley shochu and 15 kiloliters of the barley shochu distillation residual liquid. The barley shochu distillation residue was used in the following examples.

【００３３】[0033]

【実施例１】大麦焼酎製造の蒸留工程で得られた前記大
麦焼酎蒸留残液を8000rpm,10minの条件で遠心分離して
大麦焼酎蒸留残液の液体分を得、得られた液体分25Lを
オルガノ社製の合成吸着剤アンバーライトXAD-16を充填
したカラム（樹脂容量10L）に接触させ、当該カラムに
吸着する吸着画分を得、さらに前記吸着画分を吸着した
該カラムに脱イオン水10Lを接触させて得られた溶出液
を除去後、該カラムに1(wt/vol)%の 水酸化ナトリウム
溶液10Lと脱イオン水10Lをこの順番に接触させることに
より吸着画分からなる溶出液20Lを分取した。該溶出液2
0Lをオルガノ社製強酸性陽イオン交換樹脂IR-120Bを充
填したカラム（樹脂容量10L）に接触させた後に凍結乾
燥に付し、得られた凍結乾燥物270gを粉砕したところ、
褐色を呈する精製濃縮物が得られた。Example 1 The barley shochu distillation residual liquid obtained in the distillation step of barley shochu production was centrifuged at 8,000 rpm for 10 minutes to obtain a liquid content of the barley shochu distillation residual liquid, and 25 L of the obtained liquid content was obtained. A column (resin volume: 10 L) packed with a synthetic adsorbent Amberlite XAD-16 manufactured by Organo Co., Ltd. was contacted to obtain an adsorption fraction adsorbed to the column, and deionized water was further adsorbed on the column. After removing the eluate obtained by contacting 10 L, contact the column with 10 L of 1 (wt / vol)% sodium hydroxide solution and 10 L of deionized water in this order to obtain 20 L of eluate consisting of the adsorbed fraction. Was collected. The eluate 2
When 0 L was brought into contact with a column (resin volume 10 L) packed with a strong acid cation exchange resin IR-120B manufactured by Organo Corporation, freeze-dried, and 270 g of the obtained freeze-dried product was pulverized,
A purified concentrate having a brown color was obtained.

【００３４】[0034]

【比較例1】大麦焼酎製造の蒸留工程で得られた前記大
麦焼酎蒸留残液を8000rpm,10minの条件で遠心分離して
大麦焼酎蒸留残液の液体分を得、得られた液体分25Lを
真空凍結乾燥機を用いて凍結乾燥に付し、得られた凍結
乾燥物1500gを粉砕したところ、淡褐色を呈する粉末が
得られた。[Comparative Example 1] The barley shochu distillation residual liquid obtained in the distillation step of barley shochu production was centrifuged at 8000 rpm for 10 minutes to obtain a liquid content of the barley shochu distillation residual liquid, and 25 L of the obtained liquid content was obtained. Lyophilization was performed using a vacuum freeze dryer, and 1500 g of the obtained freeze-dried product was pulverized to obtain a light brown powder.

【００３５】実施例1で得られた精製濃縮物（実１）、
および比較例1で得られた大麦焼酎蒸留残液の液体分の
凍結乾燥物（比１）を以下の試験例1に供し、それぞれ
のオロチン酸誘発性脂肪肝に対する発症抑制作用を評価
した。The purified concentrate obtained in Example 1 (Ex. 1),
The freeze-dried product (ratio 1) of the liquid fraction of the barley shochu distillation residual liquid obtained in Comparative Example 1 was used in the following Test Example 1 to evaluate the onset suppressing effect on each orotate-induced fatty liver.

【００３６】[0036]

【試験例1】即ち、4週齢Wistar系雄性ラット（日本SL
C）を1群6匹として、一般的に栄養学的実験を行う際の
標準食として使用する基本食を摂取させる基本食群、該
基本食に脂肪肝を人為的に発現させる際に一般的に用い
られる1%オロチン酸を混合した対照食を与える対照食
群、該対照食に精製濃縮物（実１）1%を混合した試験食
Aを摂取させる試験食A群、及び該対照食に凍結乾燥物
（比１）1%を混合した試験食Bを摂取させる試験食B群、
の4群に分け、それぞれの群に表8に示す組成の飼料を水
道水と共に14日間自由摂取させて飼育した。飼育期間終
了後、14日間飼育後の体重増加量、14日間の飼料摂取量
を測定し、ラットを解剖後、心臓から血液を採取し、肝
臓を摘出した。採取した血液は遠心分離して血清を得、
得られた血清について、常法に従って、血清総コレステ
ロール濃度、血清HDL-コレステロール濃度、血清トリグ
リセリド濃度、及び血清リン脂質濃度を測定し、摘出し
た肝臓については、その重量、肝臓総脂質濃度、肝臓コ
レステロール濃度、肝臓トリグリセリド濃度、及び肝臓
リン脂質濃度を測定した。[Test Example 1] That is, 4-week-old Wistar male rats (Japan SL
C) with 1 group consisting of 6 animals, generally used as a standard diet when conducting nutritional experiments, a basic diet group that receives a basic diet, commonly used when artificially expressing fatty liver in the basic diet. Control food group to which a control food mixed with 1% orotic acid used in the above was fed, and a test food in which the purified food (actual 1) 1% was mixed with the control food
A test food group A to ingest A, and a test food B group to ingest test food B in which the control food was mixed with lyophilized product (ratio 1) 1%,
Were divided into 4 groups, and each group was bred by freely ingesting the feed having the composition shown in Table 8 together with tap water for 14 days. After the breeding period was completed, the amount of weight gain after breeding for 14 days and the feed intake for 14 days were measured, the rat was dissected, blood was collected from the heart, and the liver was excised. The collected blood is centrifuged to obtain serum,
For the obtained serum, the serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration were measured according to a conventional method, and the extracted liver, its weight, liver total lipid concentration, liver cholesterol The concentration, liver triglyceride concentration, and liver phospholipid concentration were measured.

【００３７】[0037]

【評価1】血清総コレステロール濃度、血清HDL-コレス
テロール濃度、血清トリグリセリド濃度、血清リン脂質
濃度肝臓重量、肝臓総脂質濃度、肝臓コレステロール濃
度、肝臓トリグリセリド濃度、肝臓リン脂質濃度、及び
肝臓重量の測定結果を表9に示す。表9に示す結果から以
下の事実が判明した。肝臓重量は対照食群で顕著に増加
し、試験食B群でもやや増加したが、試験食A群では基本
食の正常値と実質的に同等の値を示した。肝臓総脂質濃
度、肝臓コレステロール濃度、及び肝臓トリグリセリド
濃度は、対照食群では顕著に増加し、試験食B群でもや
や増加したが、試験食A群では基本食の正常値と実質的
に同等の値，又は該正常値よりも低い値を示した。一
方、血清総コレステロール濃度、血清HDL-コレステロー
ル濃度、血清トリグリセリド濃度、及び血清リン脂質濃
度は、対照食群が顕著に低下し、試験食B群も低下した
のに対して、試験食A群は基本食の正常値と実質的に同
等の値を示した。即ち、脂肪肝を人為的に発現させるオ
ロチン酸を含む対照食に凍結乾燥物（比１）を1%混合し
た試験食B群においてはオロチン酸誘発性脂肪肝に対す
る発症抑制作用が極めて小さかったのに対して、精製濃
縮物（実１）を1%混合した試験食A群においてはオロチ
ン酸誘発性脂肪肝の発症が完全に抑制された。この結果
から、本発明の精製濃縮物のオロチン酸誘発性脂肪肝に
対する発症抑制作用は、大麦焼酎蒸留残液の液体分のそ
れを卓越するものであることが判った。[Evaluation 1] Serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, serum phospholipid concentration liver weight, total liver lipid concentration, liver cholesterol concentration, liver triglyceride concentration, liver phospholipid concentration, and liver weight measurement results Is shown in Table 9. The following facts were found from the results shown in Table 9. The liver weight was significantly increased in the control diet group and slightly increased in the test diet B group, but the test diet A group showed a value substantially equivalent to the normal value of the basic diet. Liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration were significantly increased in the control diet group and slightly increased in the test diet B group, but in the test diet group A, they were substantially equivalent to the normal values of the basic diet. The value was lower than the normal value. On the other hand, the serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration were significantly reduced in the control diet group and the test diet B group, while the test diet A group was The value was substantially equivalent to the normal value of the basic diet. That is, in the test diet group B in which the lyophilized product (ratio 1) was mixed with the control diet containing orotic acid that artificially expresses fatty liver, the inhibitory effect on the occurrence of orotic acid-induced fatty liver was extremely small in the group B. On the other hand, in the test diet group A containing 1% of the purified concentrate (Exemplary 1), the onset of orotic acid-induced fatty liver was completely suppressed. From this result, it was found that the purified concentrate of the present invention has an effect of suppressing the onset of orotic acid-induced fatty liver, which is superior to that of the liquid fraction of the barley shochu distillation residual liquid.

【００３８】実施例1で得られた精製濃縮物（実１）、
および比較例1で得られた大麦焼酎蒸留残液の液体分の
凍結乾燥物(比１)を以下の試験例2に供し、それぞれのD
-ガラクトサミン誘発性肝炎に対する発症抑制作用を評
価した。The purified concentrate obtained in Example 1 (Ex. 1),
And the freeze-dried product of the liquid component of the barley shochu distillation residual liquid (Comparative 1) obtained in Comparative Example 1 was subjected to the following Test Example 2 to obtain D
-Evaluation of the suppressive effect on galactosamine-induced hepatitis.

【００３９】[0039]

【試験例2】５週令のWistar系雄性ラットを1群9匹とし
て、対照食を摂取させる対照食群、該対照食に含まれる
成分の一部を精製濃縮物（実１）2重量%で代替した試験
食Aを摂取させる試験食A群、および該対照食に含まれる
成分の一部を凍結乾燥物(比１) 2重量%で代替した試験
食Bを摂取させる試験食B群、の3群に分け、それぞれの
群に表10に示す組成の飼料を水道水と共に15日間自由摂
取させて飼育した。実験食投与14日目にD-ガラクトサミ
ンを350mg/kg体重となるようにラットの腹腔内に投与
し、22時間後にラットを屠殺後、血液を採取し、これを
遠心分離して血清を得、得られた血清について、血清中
のGOT及びGPTを測定するとともに、肝臓の病理組織学的
検索を行った。[Test Example 2] Wistar male rats aged 5 weeks were set to 9 per group, and a control diet was fed with a control diet, and some of the components contained in the control diet were purified concentrate (actual 1) 2% by weight. Test food group A in which the test food A replaced by 1. is fed, and test food group B in which the test food B in which a part of the components included in the control food is lyophilized (ratio 1) 2% by weight is taken Were divided into 3 groups, and each group was bred by freely ingesting the feed having the composition shown in Table 10 together with tap water for 15 days. On the 14th day of the administration of the experimental diet, D-galactosamine was intraperitoneally administered to the rat so as to have a dose of 350 mg / kg, and after 22 hours, the rat was sacrificed, blood was collected, and this was centrifuged to obtain serum, With respect to the obtained serum, GOT and GPT in the serum were measured, and a histopathological search of the liver was performed.

【００４０】[0040]

【評価1】血清中のGOT及びGPTの測定結果を表11に示
す。表11に示す結果から以下の事実が判明した。GOT及
びGPTの値は、試験食A群及び試験食B群が対照食群に比
べて低下したが、特に試験食A群の低下が極めて顕著で
あった。肝臓の病理組織学的検索では、対照食群の肝小
葉中心体に強くみられた肝細胞の変成・壊死が試験食A
群ではほとんど認められなかった。即ち、大麦焼酎蒸留
残液の液体分から得た本発明の精製濃縮物を混合した試
験食A群においては、D-ガラクトサミン誘発性肝炎の発
症が顕著に抑制された。この結果から、本発明の精製濃
縮物のD-ガラクトサミン誘発性肝炎に対する発症抑制作
用は、大麦焼酎蒸留残液の液体分のそれを卓越するもの
であることが判った。[Evaluation 1] Table 11 shows the measurement results of GOT and GPT in serum. The following facts were found from the results shown in Table 11. The values of GOT and GPT were lower in the test diet A group and the test diet B group than in the control diet group, but the reduction in the test diet A group was particularly remarkable. In the histopathological examination of the liver, hepatocyte degeneration and necrosis, which were strongly observed in the centrilobular body of the liver of the control diet group, were the test diet A.
Little was seen in the group. That is, in the test diet group A in which the purified concentrate of the present invention obtained from the liquid fraction of the barley shochu distillation residue was mixed, the onset of D-galactosamine-induced hepatitis was significantly suppressed. From this result, it was found that the purified concentrate of the present invention has an effect of suppressing the onset of D-galactosamine-induced hepatitis that is superior to that of the liquid fraction of the barley shochu distillation residual liquid.

【００４１】以上、試験例1及び試験例2の結果から明ら
かなように、本発明の大麦焼酎蒸留残液から得られる精
製濃縮物は、大麦焼酎蒸留残液液体分に比べて極めて強
力な肝障害発症抑制作用、即ち、オロチン酸誘発性脂肪
肝の発症を強力に抑制する作用及びD-ガラクトサミン誘
発性肝炎の発症を強力に抑制する作用を有し、大麦焼酎
蒸留残液の液体分に比べて極少量の摂取でオロチン酸誘
発性脂肪肝及びD-ガラクトサミン誘発性肝炎の発症に対
する有効な抑制作用を発揮するものであることが判明し
た。As is clear from the results of Test Example 1 and Test Example 2 above, the purified concentrate obtained from the barley shochu distillation residual liquid of the present invention has a significantly stronger liver than the barley shochu distillation residual liquid liquid content. Disorder development inhibitory effect, that is, having a strong inhibitory effect on the development of orotate-induced fatty liver and an effect of strongly suppressing the development of D-galactosamine-induced hepatitis, compared to the liquid fraction of barley shochu distillation residual liquid It was found that even ingesting a very small amount, it exerts an effective inhibitory effect on the development of orotic acid-induced fatty liver and D-galactosamine-induced hepatitis.

【００４２】[0042]

【表１】 [Table 1]

【００４３】[0043]

【表２】 [Table 2]

【００４４】[0044]

【表３】 [Table 3]

【００４５】[0045]

【表４】 [Table 4]

【００４６】[0046]

【表５】 [Table 5]

【００４７】[0047]

【表６】 [Table 6]

【００４８】[0048]

【表７】 [Table 7]

【００４９】[0049]

【表８】 [Table 8]

【００５０】[0050]

【表９】 [Table 9]

【００５１】[0051]

【表１０】 [Table 10]

【００５２】[0052]

【表１１】 [Table 11]

【００５３】[0053]

【発明の効果】以上、詳述したように本発明によれば、
大麦を原料とする焼酎製造において副成する大麦焼酎蒸
留残液を固液分離して液体分を得、該液体分を合成吸着
剤を用いる吸着処理に付して吸着画分を得、該吸着画分
をアルカリ又はエタノールを用いて溶出することによ
り、肝障害（オロチン酸誘発性脂肪肝及びD-ガラクトサ
ミン誘発性肝炎）の発症を強力に抑制する作用を有する
精製濃縮物を得ることが出来る。As described above in detail, according to the present invention,
A barley shochu distillation residual liquid, which is a by-product in the production of shochu using barley as a raw material, is subjected to solid-liquid separation to obtain a liquid content, and the liquid content is subjected to an adsorption treatment using a synthetic adsorbent to obtain an adsorption fraction. By eluting the fraction with alkali or ethanol, a purified concentrate having an action of strongly suppressing the onset of liver damage (orotic acid-induced fatty liver and D-galactosamine-induced hepatitis) can be obtained.

─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───

【手続補正書】[Procedure amendment]

【提出日】平成１４年８月２３日（２００２．８．２
３）[Submission date] August 23, 2002 (2002.8.2)
3)

【手続補正１】[Procedure Amendment 1]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】特許請求の範囲[Name of item to be amended] Claims

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【特許請求の範囲】[Claims]

【請求項２】前記合成吸着剤は、芳香族系合成吸着剤、
芳香族系修飾型合成吸着剤、又はメタクリル系合成吸着
剤である請求項1に記載の精製濃縮物。 2. The synthetic adsorbent is an aromatic synthetic adsorbent,
Aromatic modified synthetic adsorbent or methacrylic synthetic adsorbent
The purified concentrate according to claim 1, which is an agent .

【請求項３】前記脱着画分の凍結乾燥粉末からなる請求
項1又は２に記載の精製濃縮物。 3. A purified concentrate according to claim 1 or 2 consisting of a lyophilized powder of the desorption fraction.

【請求項４】食品として使用する請求項1乃至３のいず
れかに記載の精製濃縮物。 4. One of claims 1 to 3, which is used as a food.
Purification concentrate according to either Re.

【請求項５】医薬品として使用する請求項1乃至３のい
ずれかに記載の精製濃縮物。 5. The method according to any one of claims 1 to 3, which is used as a pharmaceutical product.
Purification concentrate according to Zureka.

【請求項６】請求項1に記載の精製濃縮物は、乾燥物重
量で、粗タンパク４０乃至６０重量%、ポリフェノール
７乃至１２重量%、多糖類５乃至１０重量%（糖組成：グ
ルコース０乃至２重量%、キシロース３乃至５重量%、及
びアラビノース２乃至５重量%）、有機酸４乃至１０重
量% (リンゴ酸１乃至３重量%、クエン酸２乃至４重量
%、コハク酸０乃至１重量%、乳酸０乃至６重量%、及び
酢酸０乃至１重量%)、及び遊離糖類0乃至２重量%（マル
トース０乃至１重量%、キシロース０乃至１重量%、アラ
ビノース０乃至１重量%、及びグルコース０乃至１重量
%）の成分組成を有する。 6. The purified concentrate according to claim 1, wherein the dry protein weight is 40 to 60% by weight of crude protein, 7 to 12% by weight of polyphenol, and 5 to 10% by weight of polysaccharide (sugar composition: 0 to glucose). 2% by weight, xylose 3 to 5% by weight, and arabinose 2 to 5% by weight), organic acid 4 to 10% by weight (malic acid 1 to 3% by weight, citric acid 2 to 4% by weight)
%, Succinic acid 0 to 1% by weight, lactic acid 0 to 6% by weight, and acetic acid 0 to 1% by weight), and free sugars 0 to 2% by weight (maltose 0-1% by weight, xylose 0 to 1% by weight, arabinose) 0 to 1% by weight, and glucose 0 to 1% by weight
%).

【請求項７】大麦を原料とする焼酎製造において副成す
る大麦焼酎蒸留残液を固液分離して液体分を得る工程、
該液体分を合成吸着剤を用いる吸着処理に付して吸着画
分を得る工程、及び該吸着画分をアルカリ又はエタノー
ルを用いて溶出することにより脱着画分を得る工程を順
次行うことを特徴とするオロチン酸誘発性脂肪肝及び/
又はD-ガラクトサミン誘発性肝炎の発症を抑制する作用
を有する精製濃縮物の製造方法。 7. A step of solid-liquid separating a barley shochu distillation residual liquid by-produced in the production of shochu using barley as a raw material to obtain a liquid component,
Characterized in that a step of subjecting the liquid content to an adsorption treatment using a synthetic adsorbent to obtain an adsorption fraction and a step of eluting the adsorption fraction with an alkali or ethanol to obtain a desorption fraction are sequentially performed. Orotic acid-induced fatty liver and /
Alternatively, a method for producing a purified concentrate having an action of suppressing the onset of D-galactosamine-induced hepatitis.

【請求項８】前記脱着画分を凍結乾燥する工程を更に有
する請求項７に記載の精製濃縮物の製造方法。 8. The process for producing purified concentrate of claim 7 further comprising the step of freeze drying the desorption fraction.

【請求項９】前記合成吸着剤は、芳香族系合成吸着剤、
芳香族系修飾型合成吸着剤、又はメタクリル系合成吸着
剤である請求項７又は８に記載の精製濃縮物の製造方
法。 Wherein said synthetic adsorbent, aromatic synthetic adsorbent,
Aromatic modified synthetic adsorbent or methacrylic synthetic adsorbent
A method for producing the purified concentrate according to claim 7 or 8, which is an agent.
Law .

【請求項１０】玄麦大麦又は精白大麦を原料にして製造
した大麦麹と焼酎用酵母とを発酵に付して熟成もろみを
作製し、該熟成もろみを蒸留に付して大麦焼酎を製造す
る工程（A）、及び前記工程（A）において前記大麦焼酎
を製造する際に蒸留残渣として副成する大麦焼酎蒸留残
液を固液分離して液体分を得、該液体分を合成吸着剤を
用いる吸着処理に付して吸着画分を得、該吸着画分をア
ルカリ又はエタノールを用いて溶出することにより脱着
画分からなるオロチン酸誘発性脂肪肝及び/又はD-ガラ
クトサミン誘発性肝炎の発症を抑制する作用を有する精
製濃縮物を製造する工程（B）とからなり、前記工程
（A）及び前記工程（B）を連続して行うことを特徴とす
る前記大麦焼酎及び前記精製濃縮物を連続して製造する
方法。 10. A process of producing barley shochu by fermenting barley koji and yeast for shochu produced by using barley barley or refined barley as a raw material to produce an aged moromi, and subjecting the aged moromi to distillation to produce a barley shochu. (A), and the barley shochu distillation residual liquid by-produced as a distillation residue when producing the barley shochu in the step (A) is subjected to solid-liquid separation to obtain a liquid content, and the liquid content is used as a synthetic adsorbent. Suppress the onset of orotate-induced fatty liver and / or D-galactosamine-induced hepatitis consisting of desorption fractions by adsorbing to obtain adsorption fractions and eluting the adsorption fractions with alkali or ethanol The step (B) of producing a purified concentrate having the action of, wherein the step (A) and the step (B) are continuously performed, wherein the barley shochu and the purified concentrate are continuously produced. Manufacturing method.

【請求項１１】前記工程（A）において、前記熟成もろ
みを得る際に、別に用意した玄麦大麦又は精白大麦を前
記大麦麹及び前記焼酎用酵母と共に発酵に付すことを特
徴とする請求項１０に記載の方法。 11. The step (A), in obtaining the aging mash, the crude barley barley or polished barley was prepared separately in claim 10, characterized in subjecting the fermentation with the barley koji and the shochu yeast The method described.

【請求項１２】前記合成吸着剤は、芳香族系合成吸着
剤、芳香族系修飾型合成吸着剤、又はメタクリル系合成
吸着剤である請求項１０又は１１に記載の方法。 12. The method of claim 11, wherein the synthetic adsorbent is an aromatic synthetic adsorption
Agent, aromatic modified synthetic adsorbent, or methacrylic synthetic
The method according to claim 10 or 11, which is an adsorbent .

───────────────────────────────────────────────────── フロントページの続き (72)発明者 竹嶋 直樹 大分県宇佐市大字山本2211 株式会社大麦 発酵研究所内 (72)発明者 望月 聡 大分県大分市田室町６−31−603 サーパ ス田室 (72)発明者 外薗 英樹 大分県宇佐市大字山本2231−１ 三和酒類 株式会社内 (72)発明者 梅本 泰史 大分県宇佐市大字山本2231−１ 三和酒類 株式会社内 Ｆターム(参考） 4B018 LB10 MD79 MD93 ME14 MF01 MF13 4B028 AC06 AG03 AP20 AP22 AS06 AS09 AS10 4C088 AB73 AC04 BA12 BA16 CA13 MA52 NA14 ZA75 4H055 AA01 AB10 AB27 AC62 AD20 AD31 BA30 BA50    ─────────────────────────────────────────────────── ─── Continued front page    (72) Inventor Naoki Takeshima             2211 Yamamoto, Usa, Oita Prefecture Barley Co., Ltd.             Inside the fermentation laboratory (72) Inventor Satoshi Mochizuki             6-31-603 Tamper Town, Oita City, Oita Prefecture             Su Taburo (72) Inventor Hideki Sozono             2231-1, Yamamoto, Usa City, Oita Prefecture Sanwa Sake             Within the corporation (72) Inventor Yasushi Umemoto             2231-1, Yamamoto, Usa City, Oita Prefecture Sanwa Sake             Within the corporation F term (reference) 4B018 LB10 MD79 MD93 ME14 MF01                       MF13                 4B028 AC06 AG03 AP20 AP22 AS06                       AS09 AS10                 4C088 AB73 AC04 BA12 BA16 CA13                       MA52 NA14 ZA75                 4H055 AA01 AB10 AB27 AC62 AD20                       AD31 BA30 BA50

Claims (9)

【特許請求の範囲】[Claims] 【請求項１】 大麦を原料とする焼酎製造において副成
する大麦焼酎蒸留残液を固液分離して液体分を得、該液
体分を合成吸着剤を用いる吸着処理に付して吸着画分を
得、該吸着画分をアルカリ又はエタノールを用いて溶出
することにより得られる脱着画分からなる、オロチン酸
誘発性脂肪肝及び/又はD-ガラクトサミン誘発性肝炎の
発症を抑制する作用を有する精製濃縮物。1. A barley shochu distillation residual liquid by-produced in the production of shochu using barley as a raw material is subjected to solid-liquid separation to obtain a liquid content, and the liquid content is subjected to an adsorption treatment using a synthetic adsorbent to obtain an adsorption fraction. And a desorption fraction obtained by eluting the adsorbed fraction with alkali or ethanol, a purified concentrate having an action of suppressing the occurrence of orotic acid-induced fatty liver and / or D-galactosamine-induced hepatitis. object. 【請求項２】前記脱着画分の凍結乾燥粉末からなる請求
項1に記載の精製濃縮物。2. The purified concentrate according to claim 1, which comprises a freeze-dried powder of the desorbed fraction. 【請求項３】食品として使用する請求項1又は2に記載の
精製濃縮物。3. The purified concentrate according to claim 1, which is used as a food. 【請求項４】医薬品として使用する請求項1又は2に記載
の精製濃縮物。4. The purified concentrate according to claim 1, which is used as a pharmaceutical. 【請求項５】請求項1に記載の精製濃縮物は、乾燥物重
量で、粗タンパク４０乃至６０重量%、ポリフェノール
７乃至１２重量%、多糖類５乃至１０重量%（糖組成：グ
ルコース０乃至２重量%、キシロース３乃至５重量%、及
びアラビノース２乃至５重量%）、有機酸４乃至１０重
量% (リンゴ酸１乃至３重量%、クエン酸２乃至４重量
%、コハク酸０乃至１重量%、乳酸０乃至６重量%、及び
酢酸０乃至１重量%)、及び遊離糖類0乃至２重量%（マル
トース０乃至１重量%、キシロース０乃至１重量%、アラ
ビノース０乃至１重量%、及びグルコース０乃至１重量
%）の成分組成を有する。5. The purified concentrate according to claim 1, wherein the dry matter weight is 40 to 60% by weight of crude protein, 7 to 12% by weight of polyphenol, and 5 to 10% by weight of polysaccharide (sugar composition: 0 to glucose). 2% by weight, xylose 3 to 5% by weight, and arabinose 2 to 5% by weight), organic acid 4 to 10% by weight (malic acid 1 to 3% by weight, citric acid 2 to 4% by weight)
%, Succinic acid 0 to 1% by weight, lactic acid 0 to 6% by weight, and acetic acid 0 to 1% by weight), and free sugars 0 to 2% by weight (maltose 0-1% by weight, xylose 0 to 1% by weight, arabinose) 0 to 1% by weight, and glucose 0 to 1% by weight
%). 【請求項６】大麦を原料とする焼酎製造において副成す
る大麦焼酎蒸留残液を固液分離して液体分を得る工程、
該液体分を合成吸着剤を用いる吸着処理に付して吸着画
分を得る工程、及び該吸着画分をアルカリ又はエタノー
ルを用いて溶出することにより脱着画分を得る工程を順
次行うことを特徴とするオロチン酸誘発性脂肪肝及び/
又はD-ガラクトサミン誘発性肝炎の発症を抑制する作用
を有する精製濃縮物の製造方法。6. A step of solid-liquid separating a barley shochu distillation residual liquid by-produced in the production of shochu using barley as a raw material to obtain a liquid component,
Characterized in that a step of subjecting the liquid content to an adsorption treatment using a synthetic adsorbent to obtain an adsorption fraction and a step of eluting the adsorption fraction with an alkali or ethanol to obtain a desorption fraction are sequentially performed. Orotic acid-induced fatty liver and /
Alternatively, a method for producing a purified concentrate having an action of suppressing the onset of D-galactosamine-induced hepatitis. 【請求項７】前記脱着画分を凍結乾燥する工程を更に有
する請求項６に記載の精製濃縮物の製造方法。7. The method for producing a purified concentrate according to claim 6, further comprising a step of freeze-drying the desorbed fraction. 【請求項８】玄麦大麦又は精白大麦を原料にして製造し
た大麦麹と焼酎用酵母とを発酵に付して熟成もろみを作
製し、該熟成もろみを蒸留に付して大麦焼酎を製造する
工程（A）、及び前記工程（A）において前記大麦焼酎を
製造する際に蒸留残渣として副成する大麦焼酎蒸留残液
を固液分離して液体分を得、該液体分を合成吸着剤を用
いる吸着処理に付して吸着画分を得、該吸着画分をアル
カリ又はエタノールを用いて溶出することにより脱着画
分からなるオロチン酸誘発性脂肪肝及び/又はD-ガラク
トサミン誘発性肝炎の発症を抑制する作用を有する精製
濃縮物を製造する工程（B）とからなり、前記工程（A）
及び前記工程（B）を連続して行うことを特徴とする前
記大麦焼酎及び前記精製濃縮物を連続して製造する方
法。8. A step of producing barley shochu by fermenting barley koji and yeast for shochu produced by using barley barley or polished barley as a raw material to produce an aged moromi, and subjecting the aged moromi to distillation to produce a barley shochu. (A), and the barley shochu distillation residual liquid by-produced as a distillation residue when producing the barley shochu in the step (A) is subjected to solid-liquid separation to obtain a liquid content, and the liquid content is used as a synthetic adsorbent. Suppress the onset of orotate-induced fatty liver and / or D-galactosamine-induced hepatitis consisting of desorption fractions by adsorbing to obtain adsorption fractions and eluting the adsorption fractions with alkali or ethanol And a step (B) for producing a purified concentrate having the action of
And a method for continuously producing the barley shochu and the purified concentrate, wherein the step (B) is continuously performed. 【請求項９】前記工程（A）において、前記熟成もろみ
を得る際に、別に用意した玄麦大麦又は精白大麦を前記
大麦麹及び前記焼酎用酵母と共に発酵に付すことを特徴
とする請求項８に記載の方法。9. In the step (A), when the aged moromi is obtained, separately prepared barley barley or refined white barley is subjected to fermentation together with the barley malt and the yeast for shochu. The method described.